SREBF1 and Familial prostate cancer: Follow-up studies confirmed the increased epoxycholesterol levels, including products of the LXR target gene SREBF1 during prostate cancer disease progression [40] and direct implication of LXR in PCa based on inhibited proliferation of prostate cancer cell lines by LXR agonists [41].